Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry

Semplicini C, De Antonio M, Taouagh N, Béhin A, Bouhour F, Echaniz-Laguna A, Magot A, Nadaj-Pakleza A, Orlikowski D, Sacconi S, Salort-Campana E, Solé G, Tard C, Zagnoli F, Jean-Yves H, Hamroun D, Laforêt P; French Pompe Study Group
J Inherit Metab Dis. 2020. doi: 10.1002/jimd.12272.
This study reports the findings from 158 patients treated by Enzyme Replacement Therapy and included in a French Pompe Registry.
A two-phases model described the changes in MFM scores after treatment implementation. MFM total score showed an initial significant increase (6.6% ±2.3/year) followed by a -1.13%/year (change of slope: -7.7 ±2.3, p<0.01) decline after 0.5 years. D1and D2 sub-scores showed a progressive decline (-1.0%±0.1/year, p<0.001), while D3 score showed a slow progressive decline (-0.2%±0.1/year, p<0.05), confirming that the distal muscle functions impairment is minimal in Pompe Disease..

PubMed Link

Keywords: Pompe disease, Sensitivity to change

Articles in scientific journals